Motif Neurotech Receives FDA Approval to Begin First Clinical Trial of its Therapeutic BCI for Treatment-Resistant Depression
Motif Neurotech, a brain-computer interface (BCI) company developing technologies for mental health, today announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) for the RESONATE Early Feasibility Study. The trial will evaluate the Motif XCS System, a small wirelessly powered implant that delivers gentle electrical stimulation to a brain region clinically shown to reduce the symptoms of depression in adults who have not found relief from two or more medications. This IDE approval comes only four years after the company’s founding, making Motif the fastest implantable BCI company to move from founding to IDE approval with a novel device.
Motif Neurotech Launches Patient Registry for Future Research Opportunities
Motif Neurotech, a brain-computer interface (BCI) company developing technologies for mental health, today announced that its patient registry is now live and accepting submissions from individuals with treatment-resistant depression (TRD) who may be interested in learning about potential future research opportunities.
Motif Neurotech Wins UK Government Award to Develop Therapeutic Brain-Computer Interface
Motif Neurotech, a Houston-based neurotechnology company, today announced their selection by UK’s Advanced Research and Invention Agency (ARIA) for multimillion dollar award to support Motif’s development of a therapeutic brain-computer interface (BCI) technology to treat cognitive and psychiatric conditions. The award will fund development of a network of neural devices designed to monitor and regulate mental and cognitive states without brain surgery. The award is part of ARIA’s Precision Neurotechnologies program, led by program director Jacques Carolan.
Motif Neurotech Raises $18.75 Million in Series A Financing to Advance Implantable Device for Treatment-Resistant Depression
Motif Neurotech, a neurotechnology company developing minimally-invasive bioelectronics for mental health, announced today an oversubscribed Series A financing of $18.75 million led by Arboretum Ventures, with participation from new investors KdT Ventures, Satori Neuro, Dolby Family Ventures, re.Mind Capital, individual investor Max Hodak and existing investors Divergent Capital, TMC Innovation, PsyMed Ventures, Empath Ventures and Capital Factory.
Motif Neurotech Conducts First-in-human Brain Stimulation With Millimeter-sized Implantable Device for Treatment-resistant Depression
Motif Neurotech, a neurotechnology company developing minimally invasive bioelectronics for mental health, announced today new research published to the preprint server medrxiv that demonstrates a millimeter-sized brain stimulator in a human subject.
Motif Neurotech Strengthens Leadership Team with Appointment of Steven Goetz as Chief Technology Officer
Motif Neurotech, a clinical-stage company developing minimally invasive bioelectronics for mental health, announces the appointment of Steven Goetz as Chief Technology Officer. Goetz joins Motif after more than 26 years in the Neuromodulation Operating Unit at Medtronic, where he led engineering and innovation initiatives for implantable device therapies for a wide range of diseases.
